Why is this ASX 300 stock rocketing 17% today?

MotleyFool

03/17

Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Monday. In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back. At the time of writing, the ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620418415"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620418415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620418415?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 07:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620418415","market":"hk","top_or_hot":-1,"title":"Why is this ASX 300 stock rocketing 17% today?","media":"MotleyFool","content":"<div>\n<p>Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Monday.\nIn early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.\nAt the time of writing, the ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/\">网页链接</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why is this ASX 300 stock rocketing 17% today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy is this ASX 300 stock rocketing 17% today?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MotleyFool</strong><span class=\"h-time small\">2026-03-17 07:59</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Monday.\nIn early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.\nAt the time of writing, the ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/\">MotleyFool</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/","article_id":"2620418415","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620418415","pubTimestamp":1773705549,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Clarity Pharmaceuticals Ltd  shares are having a strong session on Monday.In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.Investors appear to be responding positively to an update from the company regarding new trial data for its prostate cancer imaging technology.The company revealed that results from the Co-PSMA study were presented at the European Association of Urology  Annual Congress 2026 in London. The data has also been accepted for publication in the European Urology journal.The trial evaluated Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in patients experiencing biochemical recurrence of prostate cancer after surgery.Importantly, the study compared the ASX 300 stock's imaging technology with a current standard-of-care PSMA PET scan.The ASX 300 stock's executive chair, Dr Alan Taylor, commented:. The extraordinary quality of the academic research is coupled with the feverish pace of commercialisation where our registrational Phase III tr","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"为什么这只ASX 300股票今天飙升17%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1},"content_text":"Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Monday.\nIn early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.\nAt the time of writing, the clinical-stage radiopharmaceutical company's shares are still up around 5%.\nImage source: Getty Images\nWhy is this ASX 300 stock jumping?\nInvestors appear to be responding positively to an update from the company regarding new trial data for its prostate cancer imaging technology.\nThe company revealed that results from the Co-PSMA study were presented at the European Association of Urology (EAU) Annual Congress 2026 in London. The data has also been accepted for publication in the European Urology journal.\nThe trial evaluated Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in patients experiencing biochemical recurrence of prostate cancer after surgery.\nImportantly, the study compared the ASX 300 stock's imaging technology with a current standard-of-care PSMA PET scan.\nThe results showed that Clarity's agent detected significantly more cancer lesions than the standard scan. Across the study participants, the new imaging approach identified 63 lesions compared with 24 detected using the standard-of-care method.\nIn addition, 78% of patients had a positive scan using 64Cu-SAR-bisPSMA compared with 36% using the existing imaging agent, highlighting a potential improvement in detecting recurrent prostate cancer.\nThe study also showed a higher true positive rate and lower false negative rate for the company's imaging technology.\nWhy this matters\nDetecting prostate cancer recurrence earlier and more accurately can significantly influence treatment decisions.\nAccording to the trial data, the improved imaging results led to changes in planned patient management in 44% of participants, with many switching from surveillance to targeted radiotherapy.\nThese findings add to the growing body of evidence supporting the SAR-bisPSMA platform, which is designed as a targeted copper theranostic. This technology has the potential to be used both for cancer imaging and treatment depending on the isotope used.\nLooking ahead, the company intends to combine results from this study with data from other trials, including the Phase II COBRA study and the Phase III AMPLIFY trial.\nTogether, these results are expected to support a future regulatory submission to the US Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA in patients with recurrent prostate cancer.\nThe ASX 300 stock's executive chair, Dr Alan Taylor, commented:\nThe extraordinary quality of the academic research is coupled with the feverish pace of commercialisation where our registrational Phase III trials, AMPLIFY and CLARIFY, are nearing completion. We have recently shared that AMPLIFY reached its target number of participants with rising or detectable PSA after initial definitive treatment at clinical sites across the US and Australia in just 9 months since imaging the first patient, and we look forward to collecting and analysing the final study data.\nCombined with results from the Co-PSMA and COBRA trials, we believe it will constitute a compelling application for approval of 64Cu-SAR-bisPSMA by regulatory authorities for the BCR indication.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}